The vaccine was jointly developed by the First Affiliated Hospital under the School of Medicine of the Zhejiang University, Hong Kong University, Chinese Center for Disease Control and Prevention, National Institute for Food and Drug Control, and the Chinese Academy of Medical Sciences.
Li Lanjuan, leading researcher from the Chinese Academy of Engineering, said the team started research after they successfully isolated H7N9 bird flu virus from the throat swab sample of an infected patient on April 3.
The team applied plasmid reverse genetics and genetic reassortment, which was widely adopted by the world, to develop the vaccine seeds, which were later proved to be safe with the embryonated chicken eggs, she said.
Currently, the vaccine has passed the test on ferrets, which was conducted by the Institute of Laboratory Animal Sciences of the Chinese Academy of Medical Sciences. Drug authorities have also verified the vaccine in accordance with relevant requirements of Chinese Pharmacopoeia.
At the news conference on the research findings held Saturday in Hangzhou, capital of east China’s Zhejiang Province, medicine producers, such as Tianyuan Bio-Pharmaceutical Co., Ltd., showed interest in the vaccine’s production, although the virus has not been spread widely enough for mass inoculation.